Geode Capital Management LLC Boosts Stock Position in DiaMedica Therapeutics Inc. (NASDAQ:DMAC)

Geode Capital Management LLC grew its holdings in shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) by 29.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 306,958 shares of the company’s stock after acquiring an additional 70,070 shares during the quarter. Geode Capital Management LLC’s holdings in DiaMedica Therapeutics were worth $1,286,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new position in DiaMedica Therapeutics during the third quarter valued at about $40,000. Magnolia Capital Advisors LLC purchased a new stake in shares of DiaMedica Therapeutics during the 2nd quarter worth approximately $87,000. Finally, Blue Trust Inc. bought a new stake in shares of DiaMedica Therapeutics in the 3rd quarter worth approximately $185,000. 10.12% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of DiaMedica Therapeutics in a report on Friday, November 15th.

DiaMedica Therapeutics Stock Performance

Shares of DiaMedica Therapeutics stock opened at $5.46 on Friday. The stock has a market capitalization of $233.48 million, a P/E ratio of -9.75 and a beta of 1.46. DiaMedica Therapeutics Inc. has a 52-week low of $2.14 and a 52-week high of $6.41. The stock’s 50-day simple moving average is $5.01 and its 200 day simple moving average is $4.22.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.